[HTML][HTML] Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers
T Bekaii-Saab, MA Phelps, X Li, M Saji… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2011•ncbi.nlm.nih.gov
Purpose Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-
activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is
of significance. Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine
the safety and efficacy of selumetinib in BC.
activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is
of significance. Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine
the safety and efficacy of selumetinib in BC.
Abstract
Purpose
Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is of significance. Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine the safety and efficacy of selumetinib in BC.
ncbi.nlm.nih.gov
